The Medical Letter on Drugs and Therapeutics
Ribociclib (Kisqali) for Advanced or Metastatic Breast Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The oral cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (Kisqali – Novartis) has been approved by the FDA for use in combination with an aromatase inhibitor for first-line endocrine-based therapy in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Ribociclib is also available copackaged with the aromatase inhibitor letrozole (Femara, and generics) as Kisqali Femara Co-Pack. Ribociclib is the second CDK 4/6 inhibitor to be approved in the US for this indication; palbociclib (Ibrance) was the first.1 Abemaciclib (Verzenio), a third CDK 4/6 inhibitor, was recently approved and will be reviewed in a future issue.

STANDARD TREATMENT — An aromatase inhibitor, with or without the CDK 4/6 inhibitor palbociclib, is ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ribociclib (Kisqali) for Advanced or Metastatic Breast Cancer (online only)
Article code: 1532d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian